Doctors from the United States published in the scientific journal EBioMedicine the first results of preclinical trials of a classic vaccine against a new type of coronavirus SARS-CoV-2.
The scientists noted that the tests were guided by the experience of fighting SARS and middle East mers viruses, and thus initially knew how to act.
As explained by one of the authors of the study, associate Professor of the University of Pittsburgh Andrea Gambotto, scientists created a vaccine not based on parts of the RNA of the virus, but on fragments Of the s-protein of the virus. It is through it that SARS-CoV-2 enters the body.
In addition, American specialists have created an original system of penetration of the vaccine into the body – patch is covered with nano-needles. Thanks to them, the drug penetrates to the desired depth and forces the immune system to interact with it.
Experiments conducted on laboratory mice showed that two weeks after vaccination, the rodent immunity began to actively produce antibodies to the coronavirus. However, the animals themselves were initially healthy.
However, scientists remind that a similar scheme worked against THE mers virus. The vaccine given to healthy animals saved them from the disease for a year.
On April 2, it became known that Chinese scientists have started testing a vaccine against coronavirus in humans. However, due to the lack of patients in China, they plan to conduct large-scale research in other countries.
In March, Rospotrebnadzor reported that Russian scientists have created six prototypes of a coronavirus vaccine. Tests on volunteers will begin on June 29.